SURMOUNT-2: tirzepatide for obesity with type 2 diabetes
The obesity trial in people who also have type 2 diabetes — a harder group in which to lose weight.
Weight loss in a tougher population
People with type 2 diabetes generally lose less weight on any intervention than people without it, partly due to the metabolic effects of the disease and its medications. SURMOUNT-2 asked specifically how tirzepatide performs for weight management in adults who have both obesity and type 2 diabetes.
Who and how
The trial randomized adults with obesity and type 2 diabetes to tirzepatide 10 mg, 15 mg, or placebo, alongside lifestyle counseling, for 72 weeks. Co-primary endpoints were percent change in body weight and the proportion achieving at least 5% weight loss.
What was found
Mean weight reduction was approximately 12.8% at 10 mg and 14.7% at 15 mg, compared with roughly 3.2% on placebo. A large majority of treated participants achieved at least 5% weight loss, and glycemic control also improved. As expected, the average reductions were somewhat lower than the ~15–21% seen in SURMOUNT-1, which enrolled people without diabetes.
Clinical significance
For patients managing both conditions, the trial supported tirzepatide as an option that can produce clinically meaningful weight loss and improve blood glucose at the same time — relevant because excess weight worsens diabetes and vice versa. Decisions remain individual and clinician-led.
Limits and caveats
Trial averages are not individual guarantees; results vary widely between people. SURMOUNT-2 studied the branded product; compounded tirzepatide is not FDA-approved and was not the subject of these trials.
Why averages hide a wide range
Trial headlines report mean weight change, but individual responses vary widely around that average — some participants lose far more than the mean, others much less, and a minority respond minimally. Several factors influence where someone lands, including baseline characteristics, adherence, dose reached, concurrent diabetes medications and lifestyle. For people with type 2 diabetes specifically, certain glucose-lowering drugs can blunt weight loss, which partly explains the lower averages seen here versus trials in people without diabetes. The practical lesson is to treat trial percentages as population expectations, not personal guarantees, and to judge response over months rather than weeks. It is also why clinicians set individualized goals and reassess rather than promising a specific number. When comparing providers or plans on cost, this variability is another argument for understanding the recurring maintenance price you will actually pay, since the duration of treatment — not a single month — determines real-world cost.
Primary sources
- Garvey WT, Frías JP, Jastreboff AM, et al. Tirzepatide once weekly in people with type 2 diabetes and obesity (SURMOUNT-2). Lancet. 2023;402(10402):613-626.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216.
- U.S. Food and Drug Administration. Mounjaro and Zepbound (tirzepatide) prescribing information. Eli Lilly and Company.
Citations are provided for educational reference. This article summarizes published research in plain language and is not medical advice. Always consult a licensed clinician.
Common questions
What did SURMOUNT-2 show?
In adults with obesity and type 2 diabetes, tirzepatide reduced body weight by about 12.8% (10 mg) and 14.7% (15 mg) over 72 weeks, versus about 3.2% with placebo.
Why was weight loss lower than in SURMOUNT-1?
People with type 2 diabetes typically lose less weight than those without it, so somewhat smaller average reductions are expected.
Does tirzepatide help diabetes and weight together?
In SURMOUNT-2 it improved both weight and glycemic control, which is clinically useful since the two conditions reinforce each other.